Corbus Shares Drop After Initial Results for Oral Obesity Treatment CRB-913
Corbus Pharmaceuticals Phase 1 Study Results: Corbus (CRBP) shares fell approximately 3% after reporting results from its phase 1 study of CRB-913, an oral treatment for chronic obesity, which included both single and multiple ascending dose cohorts.
Efficacy and Safety Findings: The multiple ascending dose cohort of obese patients experienced a mean placebo-adjusted weight loss of 2.9% by day 14, with the drug being well tolerated and no serious adverse events reported, although mild anxiety and irritability were noted in some patients.
Market Reaction and Financial Updates: Corbus's stock price dropped 17% following a $75 million fundraising effort priced at $13 per share, alongside a GAAP EPS loss of -$1.90, which missed expectations by $0.16.
Ongoing Developments: The company continues to focus on its drug development efforts, with discussions around data updates and insights from other studies, including those related to head and neck cancer.
Trade with 70% Backtested Accuracy
Analyst Views on CRBP
About CRBP
About the author
Corbus Pharmaceuticals Reports 2025 Financial Results and Clinical Updates
- CRB-701 Clinical Data: At the 2025 ESMO, Corbus presented promising efficacy data for CRB-701 in head and neck squamous cell carcinoma and cervical cancer, with an unconfirmed objective response rate of 47.6% in HNSCC, highlighting its potential in treating challenging tumors.
- CRB-913 Weight Loss Results: In the 14-day SAD/MAD study of CRB-913, patients experienced a 2.9% weight loss with favorable GI safety, suggesting it could serve as a novel long-term management solution for chronic obesity patients.
- Funding Update: Corbus completed a $75 million public offering in Q4 2025, extending its cash runway into 2028, thereby enhancing financial stability to support future clinical development.
- Financial Performance: For Q4 2025, Corbus reported a net loss of approximately $20.6 million, significantly up from $9.5 million in Q4 2024, primarily due to increased clinical development expenses, indicating ongoing investment in R&D.
Corbus Pharmaceuticals Reports Q4 2025 Financial Results
- Financial Highlights: Corbus Pharmaceuticals reported a Q4 2025 GAAP EPS of -$1.25, beating expectations by $0.40, indicating some improvement in financial performance despite ongoing losses.
- Cash Position: As of December 31, 2025, the company had $163.3 million in cash, cash equivalents, and investments, which is expected to fund operations into 2028, demonstrating a solid financial buffer for ongoing projects.
- Capital Raising: In Q4 2025, Corbus completed a public offering that raised $75 million in gross proceeds, providing crucial funding for future R&D and operational needs, thereby enhancing its competitive position in the market.
- Market Outlook: Despite a decline in early-stage results for the obesity drug CRB-913, the approaching summer 2026 obesity data catalyst keeps market sentiment cautiously optimistic, reflecting investor expectations for potential growth opportunities.
Corbus Pharmaceuticals: 46% Stake Held by Retail Investors Influencing Management
- Retail Influence: Corbus Pharmaceuticals has 46% of its shares held by retail investors, indicating significant influence over management and strategic decisions, which could drive the company towards more public-interest-aligned directions.
- Institutional Participation: Institutional investors own 23% of the company, which brings credibility from professional investors but also raises the risk of a 'crowded trade' in a company lacking a growth history.
- Hedge Fund Role: Hedge funds hold 24% of the shares and may attempt to influence management to create short-term value, particularly driven by major shareholders like Cormorant Asset Management and OrbiMed Advisors.
- Insider Ownership: Insiders own less than 1% of the company, which may challenge other shareholders in holding management accountable for decisions, especially given the market capitalization of only $156 million.
Biotech Surge Post-Market: Inspira, MediciNova, and DiaMedica Therapeutics Among Top Performers
Biotech Stocks Performance: Several small-cap biotech and healthcare companies saw notable gains in after-hours trading, driven by recent corporate updates and clinical milestones.
Inspira Technologies Update: Inspira Technologies Oxy B.H.N. Ltd. rose 5.88% following a recent agreement for a registered direct offering and a Standby Equity Purchase Agreement, despite no new news on the day.
MediciNova's Clinical Trial Success: MediciNova, Inc. advanced 4.83% after successfully completing patient enrollment in its Phase 2 OXTOX study, which evaluates MN-166 for preventing chemotherapy-induced peripheral neuropathy.
DiaMedica's FDA Meeting: DiaMedica Therapeutics Inc. gained 2.89% after a productive pre-IND meeting with the FDA regarding its study of DM199 in preeclampsia, with an additional non-clinical study requested.
Corbus Shares Drop After Initial Results for Oral Obesity Treatment CRB-913
Corbus Pharmaceuticals Phase 1 Study Results: Corbus (CRBP) shares fell approximately 3% after reporting results from its phase 1 study of CRB-913, an oral treatment for chronic obesity, which included both single and multiple ascending dose cohorts.
Efficacy and Safety Findings: The multiple ascending dose cohort of obese patients experienced a mean placebo-adjusted weight loss of 2.9% by day 14, with the drug being well tolerated and no serious adverse events reported, although mild anxiety and irritability were noted in some patients.
Market Reaction and Financial Updates: Corbus's stock price dropped 17% following a $75 million fundraising effort priced at $13 per share, alongside a GAAP EPS loss of -$1.90, which missed expectations by $0.16.
Ongoing Developments: The company continues to focus on its drug development efforts, with discussions around data updates and insights from other studies, including those related to head and neck cancer.
Corbus Pharmaceuticals' CRB-913 Achieves 2.9% Weight Loss in Obese Patients
- Clinical Trial Success: Corbus has completed the single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1a studies of CRB-913, with all doses being safe and well-tolerated, and no serious adverse events reported, indicating a strong safety profile.
- Significant Weight Loss Effect: In the 150 mg cohort, all CRB-913-treated participants (n=9) achieved a mean weight loss of 2.9% by Day 14, while none in the placebo group (n=3) lost weight, highlighting the drug's potential in obesity management.
- Follow-up Research Plans: Corbus has initiated the 12-week Phase 1b CANYON-1 study, targeting 240 obese, non-diabetic participants, with completion expected in summer 2026, to further validate the efficacy of CRB-913.
- Broad Market Potential: As a peripherally restricted CB1 inverse agonist with reduced brain penetration, CRB-913 may offer a new treatment option for obesity, particularly when used in combination with existing therapies, presenting significant market opportunities.
Corbus Pharmaceuticals Reports 2025 Financial Results and Clinical Updates
- CRB-701 Clinical Data: At the 2025 ESMO, Corbus presented promising efficacy data for CRB-701 in head and neck squamous cell carcinoma and cervical cancer, with an unconfirmed objective response rate of 47.6% in HNSCC, highlighting its potential in treating challenging tumors.
- CRB-913 Weight Loss Results: In the 14-day SAD/MAD study of CRB-913, patients experienced a 2.9% weight loss with favorable GI safety, suggesting it could serve as a novel long-term management solution for chronic obesity patients.
- Funding Update: Corbus completed a $75 million public offering in Q4 2025, extending its cash runway into 2028, thereby enhancing financial stability to support future clinical development.
- Financial Performance: For Q4 2025, Corbus reported a net loss of approximately $20.6 million, significantly up from $9.5 million in Q4 2024, primarily due to increased clinical development expenses, indicating ongoing investment in R&D.
Corbus Pharmaceuticals Reports Q4 2025 Financial Results
- Financial Highlights: Corbus Pharmaceuticals reported a Q4 2025 GAAP EPS of -$1.25, beating expectations by $0.40, indicating some improvement in financial performance despite ongoing losses.
- Cash Position: As of December 31, 2025, the company had $163.3 million in cash, cash equivalents, and investments, which is expected to fund operations into 2028, demonstrating a solid financial buffer for ongoing projects.
- Capital Raising: In Q4 2025, Corbus completed a public offering that raised $75 million in gross proceeds, providing crucial funding for future R&D and operational needs, thereby enhancing its competitive position in the market.
- Market Outlook: Despite a decline in early-stage results for the obesity drug CRB-913, the approaching summer 2026 obesity data catalyst keeps market sentiment cautiously optimistic, reflecting investor expectations for potential growth opportunities.
Corbus Pharmaceuticals: 46% Stake Held by Retail Investors Influencing Management
- Retail Influence: Corbus Pharmaceuticals has 46% of its shares held by retail investors, indicating significant influence over management and strategic decisions, which could drive the company towards more public-interest-aligned directions.
- Institutional Participation: Institutional investors own 23% of the company, which brings credibility from professional investors but also raises the risk of a 'crowded trade' in a company lacking a growth history.
- Hedge Fund Role: Hedge funds hold 24% of the shares and may attempt to influence management to create short-term value, particularly driven by major shareholders like Cormorant Asset Management and OrbiMed Advisors.
- Insider Ownership: Insiders own less than 1% of the company, which may challenge other shareholders in holding management accountable for decisions, especially given the market capitalization of only $156 million.
Biotech Surge Post-Market: Inspira, MediciNova, and DiaMedica Therapeutics Among Top Performers
Biotech Stocks Performance: Several small-cap biotech and healthcare companies saw notable gains in after-hours trading, driven by recent corporate updates and clinical milestones.
Inspira Technologies Update: Inspira Technologies Oxy B.H.N. Ltd. rose 5.88% following a recent agreement for a registered direct offering and a Standby Equity Purchase Agreement, despite no new news on the day.
MediciNova's Clinical Trial Success: MediciNova, Inc. advanced 4.83% after successfully completing patient enrollment in its Phase 2 OXTOX study, which evaluates MN-166 for preventing chemotherapy-induced peripheral neuropathy.
DiaMedica's FDA Meeting: DiaMedica Therapeutics Inc. gained 2.89% after a productive pre-IND meeting with the FDA regarding its study of DM199 in preeclampsia, with an additional non-clinical study requested.
Corbus Shares Drop After Initial Results for Oral Obesity Treatment CRB-913
Corbus Pharmaceuticals Phase 1 Study Results: Corbus (CRBP) shares fell approximately 3% after reporting results from its phase 1 study of CRB-913, an oral treatment for chronic obesity, which included both single and multiple ascending dose cohorts.
Efficacy and Safety Findings: The multiple ascending dose cohort of obese patients experienced a mean placebo-adjusted weight loss of 2.9% by day 14, with the drug being well tolerated and no serious adverse events reported, although mild anxiety and irritability were noted in some patients.
Market Reaction and Financial Updates: Corbus's stock price dropped 17% following a $75 million fundraising effort priced at $13 per share, alongside a GAAP EPS loss of -$1.90, which missed expectations by $0.16.
Ongoing Developments: The company continues to focus on its drug development efforts, with discussions around data updates and insights from other studies, including those related to head and neck cancer.
Corbus Pharmaceuticals' CRB-913 Achieves 2.9% Weight Loss in Obese Patients
- Clinical Trial Success: Corbus has completed the single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1a studies of CRB-913, with all doses being safe and well-tolerated, and no serious adverse events reported, indicating a strong safety profile.
- Significant Weight Loss Effect: In the 150 mg cohort, all CRB-913-treated participants (n=9) achieved a mean weight loss of 2.9% by Day 14, while none in the placebo group (n=3) lost weight, highlighting the drug's potential in obesity management.
- Follow-up Research Plans: Corbus has initiated the 12-week Phase 1b CANYON-1 study, targeting 240 obese, non-diabetic participants, with completion expected in summer 2026, to further validate the efficacy of CRB-913.
- Broad Market Potential: As a peripherally restricted CB1 inverse agonist with reduced brain penetration, CRB-913 may offer a new treatment option for obesity, particularly when used in combination with existing therapies, presenting significant market opportunities.
